|
GB202016611D0
|
|
Binding molecules
|
|
WO2020229844A1
|
|
Binding molecules
|
|
GB201914468D0
|
|
Binding Molecules
|
|
GB201906872D0
|
|
Binding molecules
|
|
GB201906870D0
|
|
Binding molecules
|
|
WO2019092451A1
|
|
Single Domain Antibodies that Bind to CD137
|
|
GB201818460D0
|
|
Single domain antibodies that bind human serum albumin
|
|
GB201808589D0
|
|
Single domain antibodies that bind CD137
|
|
GB201802573D0
|
|
Therapeutic molecules that bind to LAG3
|
|
US2019322749A1
|
|
Single Domain Antibodies to Programmed Cell Death (PD-1)
|
|
GB201718734D0
|
|
Single domain antibodies that bind to CD137
|
|
GB201718735D0
|
|
Bispecific molecules that bind to CD137 and PSMA
|
|
GB201711068D0
|
|
Therapeutic molecules binding PSMA
|
|
EP3402825A1
|
|
Molecules that bind prostate specific membrane antigen (psma)
|
|
GB201700208D0
|
|
Single domain antibodies to programmed cell death (PD-1)
|
|
GB201700207D0
|
|
Single domain antibodies to prgrammed cell death (PD-1)
|
|
GB201700210D0
|
|
Single domain antibodies to programmed cell death (PD-1)
|
|
GB201612043D0
|
|
Composition for treatment of disorders
|
|
GB202011441D0
|
|
Transgenic Mice
|
|
US2017306039A1
|
|
Human vh domain scaffolds
|
